Evaluation of pharmacokinetic and pharmacodynamic properties of rapid-acting insulin analogs [insulin lispro, insulin aspart] given as a bolus by continuous subcutaneous insulin infusion (CSII) and in multiple daily injections basal-bolus therapy in pediatric subjects with type 1 diabetes (TID)

Trial Profile

Evaluation of pharmacokinetic and pharmacodynamic properties of rapid-acting insulin analogs [insulin lispro, insulin aspart] given as a bolus by continuous subcutaneous insulin infusion (CSII) and in multiple daily injections basal-bolus therapy in pediatric subjects with type 1 diabetes (TID)

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2016

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin detemir (Primary) ; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 23 Aug 2016 Status changed from recruiting to completed.
    • 28 Feb 2012 Results published in Diabetes Care.
    • 26 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top